Key Points
- Adar1 Capital Management bought 3,553 NextCure shares at an average $5.10 each, increasing its position by 0.49% to 733,270 shares. The purchase was disclosed in an SEC filing.
- NextCure shares opened at $5.72, up 9.6%, but remained below their 50-day and 200-day moving averages; the stock’s 52-week range is $1.55 to $15.74.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and a $19 average price target. NextCure also missed quarterly earnings expectations, reporting a $2.80 loss per share versus the $1.95 consensus loss.
NextCure, Inc. (NASDAQ:NXTC - Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 3,553 shares of the business's stock in a transaction that occurred on Tuesday, October 27th. The shares were purchased at an average cost of $5.10 per share, for a total transaction of $18,120.30. Following the completion of the transaction, the insider directly owned 733,270 shares in the company, valued at $3,739,677. The trade was a 0.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Monday, October 26th, Adar1 Capital Management, Llc acquired 1,672 shares of NextCure stock. The shares were purchased at an average price of $5.03 per share, with a total value of $8,410.16.
- On Friday, October 23rd, Adar1 Capital Management, Llc bought 5,626 shares of NextCure stock. The stock was purchased at an average cost of $4.83 per share, with a total value of $27,173.58.
- On Friday, July 31st, Adar1 Capital Management, Llc bought 36,303 shares of NextCure stock. The stock was purchased at an average cost of $4.94 per share, with a total value of $179,336.82.
- On Thursday, July 30th, Adar1 Capital Management, Llc bought 292,850 shares of NextCure stock. The stock was purchased at an average price of $4.93 per share, for a total transaction of $1,443,750.50.
- On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The shares were purchased at an average price of $5.00 per share, for a total transaction of $17,050.00.
NextCure Trading Up 9.6%
NASDAQ:NXTC opened at $5.72 on Wednesday. The company's 50 day moving average price is $6.11 and its 200-day moving average price is $7.99. NextCure, Inc. has a 52 week low of $1.55 and a 52 week high of $15.74.
NextCure (NASDAQ:NXTC - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) earnings per share for the quarter, missing analysts' consensus estimates of ($1.95) by ($0.85).
Analyst Ratings Changes
A number of analysts have commented on NXTC shares. Weiss Ratings lowered NextCure from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday. HC Wainwright reaffirmed a "buy" rating on shares of NextCure in a report on Thursday, August 13th. Finally, Wall Street Zen raised NextCure from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, NextCure has a consensus rating of "Hold" and an average target price of $19.00.
Read Our Latest Analysis on NXTC
Institutional Inflows and Outflows
A hedge fund recently raised its position in NextCure stock. Renaissance Technologies LLC increased its stake in shares of NextCure, Inc. (NASDAQ:NXTC - Free Report) by 80.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,534 shares of the company's stock after purchasing an additional 26,900 shares during the period. Renaissance Technologies LLC owned approximately 1.68% of NextCure worth $647,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 42.65% of the company's stock.
About NextCure
(
Get Free Report)
NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company's research is aimed at identifying and targeting biological mechanisms that suppress the immune system's ability to recognize and attack tumor cells.
NextCure's product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.
Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
